According to statistics, in the first five months in 2018, 216 combined applications of invention patents, utility model and designs were filed in Kashgar, Xinjiang, including 22 invention patents, 151 utility model patents and 42 design patents.
As of July this year, 34 GI trademarks have been licensed to 332 enterprises and agricultural specialties in Guangyuan City, Sichuan province, which have achieved good economic returns.
Recently, 428 innovation and start-up projects were approved for attending the 7th China Innovation and Entrepreneurship Competition and the 4th “Kechuang Cup” Competition in Hainan Province. More than 68% of projects were mobile internet ones.
The number of patent agencies increased from 24 at the end of 2015 to currently 41 in Jiangxi province, and 55.9% of patent applications were handled by those agencies since the province was approved to be the pilot province in 2016. The E-filing rate was 99.99%.
It's been less than a year since Beijing cut back red tape on drug approvals and already Chinese patients can expect to get some breakthrough medicines before Americans. After decades of being starved of innovative treatments for serious conditions like cancer, diabetes and kidney disease, China's 1.4 billion people are becoming global pharma's prime target. They've got more medical insurance than ever and millions are paying out of their own pockets for western treatments that aren't covered.
——To Get the Latest Drugs, Head to China, by Today
Cutting back red tape on drug approvals is a measure of China to improve people's livelihood. As self-developed drug is highly cost, difficult and has long cycle, only strict intellectual property protection can effectively guarantee the initiative of enterprises focusing on the research and development of original drugs.